Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Toripalimab plus donafenib in advanced hepatocellular carcinoma
CTR20192680Phase 2Active
- Sponsor
- Zelgen
- Start
- Oct 2020
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of toripalimab, donafenib in hepatocellular carcinoma (HCC), sponsored by Zelgen. Started Oct 2020; status: active.
02
Drugs
toripalimabdonafenib
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on CTR20192680.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20192680.